Cannabinoids, cannabis, and cannabis-based medicine for pain management

A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials

Emma Fisher, Christopher Eccleston, Louisa Degenhardt, David P. Finn, Nanna B. Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S.C. Rice, Michael Rowbotham, Mark Wallace, R. Andrew Moore

Research output: Contribution to journalReview article

Abstract

Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).

Original languageEnglish
Article numbere741
Pages (from-to)1-3
Number of pages3
JournalPain Reports
Volume4
Issue number3
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • Cannabinoids
  • Cannabis
  • Meta-analysis
  • Overview
  • Pain
  • Protocol
  • Systematic review

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Cannabinoids, cannabis, and cannabis-based medicine for pain management : A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. / Fisher, Emma; Eccleston, Christopher; Degenhardt, Louisa; Finn, David P.; Finnerup, Nanna B.; Gilron, Ian; Haroutounian, Simon; Krane, Elliot; Rice, Andrew S.C.; Rowbotham, Michael; Wallace, Mark; Andrew Moore, R.

In: Pain Reports, Vol. 4, No. 3, e741, 01.05.2019, p. 1-3.

Research output: Contribution to journalReview article

Fisher, E, Eccleston, C, Degenhardt, L, Finn, DP, Finnerup, NB, Gilron, I, Haroutounian, S, Krane, E, Rice, ASC, Rowbotham, M, Wallace, M & Andrew Moore, R 2019, 'Cannabinoids, cannabis, and cannabis-based medicine for pain management: A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials', Pain Reports, vol. 4, no. 3, e741, pp. 1-3. https://doi.org/10.1097/PR9.0000000000000741
Fisher, Emma ; Eccleston, Christopher ; Degenhardt, Louisa ; Finn, David P. ; Finnerup, Nanna B. ; Gilron, Ian ; Haroutounian, Simon ; Krane, Elliot ; Rice, Andrew S.C. ; Rowbotham, Michael ; Wallace, Mark ; Andrew Moore, R. / Cannabinoids, cannabis, and cannabis-based medicine for pain management : A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. In: Pain Reports. 2019 ; Vol. 4, No. 3. pp. 1-3.
@article{8132cfa24eff41b4b4355f2e99c1d421,
title = "Cannabinoids, cannabis, and cannabis-based medicine for pain management: A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials",
abstract = "Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30{\%} and (2) 50{\%} reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).",
keywords = "Cannabinoids, Cannabis, Meta-analysis, Overview, Pain, Protocol, Systematic review",
author = "Emma Fisher and Christopher Eccleston and Louisa Degenhardt and Finn, {David P.} and Finnerup, {Nanna B.} and Ian Gilron and Simon Haroutounian and Elliot Krane and Rice, {Andrew S.C.} and Michael Rowbotham and Mark Wallace and {Andrew Moore}, R.",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/PR9.0000000000000741",
language = "English",
volume = "4",
pages = "1--3",
journal = "Pain Reports",
issn = "2471-2531",
publisher = "Lippincott Williams & Wilkins",
number = "3",

}

TY - JOUR

T1 - Cannabinoids, cannabis, and cannabis-based medicine for pain management

T2 - A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials

AU - Fisher, Emma

AU - Eccleston, Christopher

AU - Degenhardt, Louisa

AU - Finn, David P.

AU - Finnerup, Nanna B.

AU - Gilron, Ian

AU - Haroutounian, Simon

AU - Krane, Elliot

AU - Rice, Andrew S.C.

AU - Rowbotham, Michael

AU - Wallace, Mark

AU - Andrew Moore, R.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).

AB - Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).

KW - Cannabinoids

KW - Cannabis

KW - Meta-analysis

KW - Overview

KW - Pain

KW - Protocol

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85071118600&partnerID=8YFLogxK

U2 - 10.1097/PR9.0000000000000741

DO - 10.1097/PR9.0000000000000741

M3 - Review article

VL - 4

SP - 1

EP - 3

JO - Pain Reports

JF - Pain Reports

SN - 2471-2531

IS - 3

M1 - e741

ER -